Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition

被引:52
作者
Haufroid, Vincent [1 ,2 ]
机构
[1] Hop St Luc, Analyt Chem Lab, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol LTAP, B-1200 Brussels, Belgium
关键词
Pharmacogenomics; ABCB1; ABCC2; intracellular concentrations; genotype; polymorphism; mdr1; mrp2; SINGLE-NUCLEOTIDE POLYMORPHISMS; MULTIDRUG-RESISTANCE GENE; TACROLIMUS DOSE REQUIREMENTS; MDR1 C3435T POLYMORPHISM; STEADY-STATE PHARMACOKINETICS; INTESTINAL P-GLYCOPROTEIN; LUNG-TRANSPLANT PATIENTS; RENAL-TRANSPLANT; TROUGH CONCENTRATIONS; MYCOPHENOLIC-ACID;
D O I
10.2174/138945011795378487
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ATP-binding cassette (ABC) transporter superfamily comprises membrane proteins that translocate a variety of substrates across extra- and intra-cellular membranes, and act as efflux proteins. ABC transporters are characterised by the presence of genetic polymorphisms mainly represented by single nucleotide polymorphisms (SNPs), some of which having an impact on their activity. Besides physiological substances, drugs are also substrates of some ABC transporters, mainly ABCB1, ABCC1, ABCC2, ABCC3 and ABCG2. Identifying the impact of these polymorphisms on the pharmacokinetics (PK) of these drugs may have important clinical implications, certainly for those characterised by a narrow therapeutic index and significant inter- and intra-patient PK variability. This review focuses specifically on ABCB1 and ABCC2 and critically analyses important publications dealing with the influence of ABCB1 and/or ABCC2 polymorphisms on drug disposition in humans. For different reasons discussed in this paper, the effect of ABCB1 and/or ABCC2 polymorphisms on drug concentrations in blood is not always easy to interpret and to correlate with pharmacological effects. In contrast, intracellular or target tissue drug concentrations appear more directly influenced by these polymorphisms, as illustrated with intralymphocyte concentrations for immunosupressants and antiretrovirals or with cerebrospinal fluid (CSF) concentrations for antiepileptics and antidepressants. Further research on intracellular and/or target tissue drug concentrations are still needed to better characterise the PK-PG (pharmacogenetics) relationship involving ABC transporters.
引用
收藏
页码:631 / 646
页数:16
相关论文
共 153 条
[1]   Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration [J].
Aarnoudse, Albert-Jan L. H. J. ;
Dieleman, Jeanne P. ;
Visser, Loes E. ;
Arp, Pascal P. ;
van der Heiden, Ilse P. ;
van Schaik, Ron H. N. ;
Molokhia, Mariam ;
Hofman, Albert ;
Uitterlinden, Andre G. ;
Stricker, Bruno H. Ch. .
PHARMACOGENETICS AND GENOMICS, 2008, 18 (04) :299-305
[2]   The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients [J].
Akbas, S. H. ;
Bilgen, T. ;
Keser, I. ;
Tuncer, M. ;
Yucetin, L. ;
Tosun, O. ;
Gultekin, M. ;
Luleci, G. .
TRANSPLANTATION PROCEEDINGS, 2006, 38 (05) :1290-1292
[3]   Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy [J].
Anglicheau, D ;
Le Corre, D ;
Lechaton, S ;
Laurent-Puig, P ;
Kreis, H ;
Beaune, P ;
Legendre, C ;
Thervet, E .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (03) :595-603
[4]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[5]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[6]   C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation [J].
Baldelli, Sara ;
Merlin, Simona ;
Perico, Norberto ;
Nicastri, Annalisa ;
Cortinovis, Monica ;
Gotti, Eliana ;
Remuzzi, Giuseppe ;
Cattaneo, Dario .
PHARMACOGENOMICS, 2007, 8 (09) :1127-1141
[7]   The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy [J].
Basic, Silvio ;
Hajnsek, Sanja ;
Bozina, Nada ;
Filipcic, Igor ;
Sporis, Davor ;
Mislov, Damir ;
Posavec, Ana .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2008, 17 (06) :524-530
[8]   Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms [J].
Bernsdorf, A ;
Giessmann, T ;
Modess, C ;
Wegner, D ;
Igelbrink, S ;
Hecker, U ;
Haenisch, S ;
Cascorbi, I ;
Terhaag, B ;
Siegmund, W .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (04) :440-450
[9]   Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel [J].
Bosch, Tessa M. ;
Huitema, Alwin D. R. ;
Doodeman, Valerie D. ;
Jansen, Robert ;
Witteveen, Els ;
Smit, Wim M. ;
Jansen, Rob L. ;
van Herpen, Carla M. ;
Soesan, Marcel ;
Beijnen, Jos H. ;
Schellens, Jan H. M. .
CLINICAL CANCER RESEARCH, 2006, 12 (19) :5786-5793
[10]   Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans [J].
Brunner, M ;
Langer, O ;
Sunder-Plassmann, R ;
Dobrozemsky, G ;
Müller, U ;
Wadsak, W ;
Krcal, A ;
Karch, R ;
Mannhalter, C ;
Dudczak, R ;
Kletter, K ;
Steiner, I ;
Baumgartner, C ;
Müller, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :182-190